In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Channel Preference Versus Promotional Reality: The Core Challenge Of Multichannel Marketing

Executive Summary

Pharma is one of the last industries to hold on to the use of sales representatives to sell its goods. It's time to harness digital technologies that enable multiple ways to approach clients on their own terms.

You may also be interested in...



KOL Webinars Get Maximum Bang For Pharma's Digital Buck?

Digital channels are expected to consume more of pharma's marketing dollars – China and the US already trump the rest of the world in terms of non-personal digital spends, while pharma marketers see webinars with key opinion leaders (KOLs) as the channel that generates the highest return on investment (ROI).

Evolving Pharma Sales Strategies – Are You Doing It Right?

As sales forces decline and market strategies evolve, pharma companies are increasingly employing the key account management method to interact with customers, but they are not implementing it properly. This will prove a critical mistake if not corrected, says Datamonitor Healthcare in a new report.

Five-Point Plan For Mastering Customer Preference

QuintilesIMS' research demonstrates that the preference for one set of digital channels varies widely by HCP specialty and country. A single physician’s channel preference can vary by the disease area for which they receive communication. How can companies, faced with such complexity, ever hope to master customer preference?

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel